Affiliation:
1. Center for Thoracic Oncology Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York New York USA
2. Unit of Clinical Pharmacology and Pharmacogenetics Department of Clinical and Experimental Medicine University of Pisa Pisa Italy
3. Department of Onco‐Hematology Papardo Hospital Messina Italy
Abstract
During lung carcinogenesis, different epigenetic changes occur and, among these, DNA methylation aberrations play a critical role, representing an appealing biomarker for cancer screening. In this Cancer issue, Zhao et al. systematically assessed the associations of genetically predicted DNA methylation CpGs with non–small cell lung cancer risk.